Seres Therapeutics Inc’s (NASDAQ: MCRB) Stock Price Will Be Bearish Or Bullish In 2024

Seres Therapeutics Inc (NASDAQ:MCRB) shares, rose in value, with the stock price down by -4.88% to the previous day’s close as strong demand from buyers drove the stock to $0.73.

Actively observing the price movement in the last trading, the stock closed the session at $0.76. The value of beta (5-year monthly) was 2.27. Referring to stock’s 52-week performance, its high was $6.87, and the low was $0.73. On the whole, MCRB has fluctuated by -36.35% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


With the market capitalization of Seres Therapeutics Inc currently standing at about $109.57 million, investors are eagerly awaiting this quarter’s results, scheduled for May 07, 2024 – May 13, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.34, which is expected to increase to -$0.2 for fiscal year -$1.14 and then to about -$0.8 by fiscal year 2025. Data indicates that the EPS growth is expected to be -28.10% in 2025, while the next year’s EPS growth is forecast to be 29.80%.

According to the average forecast, sales growth in current quarter could jump down -81.90%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $1.36 million, representing a decrease of -98.90% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that MCRB’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of MCRB currently trading nearly -12.37% and -27.75% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 33.16, while the 7-day volatility ratio is showing 5.92% which for the 30-day chart, stands at 8.10%. Furthermore, Seres Therapeutics Inc (MCRB)’s beta value is 2.25, and its average true range (ATR) is 0.07.

A comparison of Seres Therapeutics Inc (MCRB) with its peers suggests the former has fared considerably weaker in the market. MCRB showed an intraday change of -4.88% in last session, and over the past year, it shrunk by -87.20%%.

Data on historical trading for Seres Therapeutics Inc (NASDAQ:MCRB) indicates that the trading volumes over the past 10 days have averaged 3.08 million and over the past 3 months, they’ve averaged 4.65 million. According to company’s latest data on outstanding shares, there are 135.04 million shares outstanding.

Nearly 24.42% of Seres Therapeutics Inc’s shares belong to company insiders and institutional investors own 44.23% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 18.4 million shares as on Mar 15, 2024, resulting in a short ratio of 3.79. According to the data, the short interest in Seres Therapeutics Inc (MCRB) stood at 12.18% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 15.59 million. The stock has fallen by -48.17% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MCRB stock heading into the next quarter.